Eye - diabetic macular oedema

The PBS subsidises aflibercept, dexamethasone intravitreal implant and ranibizumab for patients with diabetic macular oedema (DMO).

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with aflibercept, dexamethasone intravitreal implant and ranibizumab under the National Health Act 1953, Section 85 for patients with DMO.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing aflibercept, dexamethasone intravitreal implant and ranibizumab.

Treatment specifics

Patients must be treated by an opthamologist or in consultation with an opthamologist to be eligible for PBS subsidised treatment with these medications.

Applications for initial treatment

Apply for authority approval to prescribe initial PBS subsidised aflibercept, dexamethasone intravitreal implant and ranibizumab to treat patients with DMO in writing and either:

All applications must include the completed:

If urgent, you can fax the first authority application to us on 1300 093 177. Our operating hours are Monday to Friday from 8 am to 5 pm AEST. Then the PBS Complex Drugs Programs Team will call you.

Applications for continuing treatment

Continuing authority applications to prescribe PBS subsidised aflibercept, dexamethasone intravitreal implant and ranibizumab to treat DMO can be made either:

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 1 June 2020